60 likes | 296 Views
Biosimilars are copied versions of biologics that offer a 20-50% reduction in cost compared with innovative biologic products. Biosimilars are getting the world wide attention as the cost of the innovative biologics are enormously high and even minimal reduction in price will reduce the healthcare spending substantially.
E N D
BIOSIMILARS - Regulatory Framework and Pipeline Analysis By RnRMarketResearch Browse more reports on Pharmaceuticals at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
BIOSIMILARS - Regulatory Framework and Pipeline Analysis Biosimilars are copied versions of biologics that offer a 20-50% reduction in cost compared with innovative biologic products. Biosimilars are getting the world wide attention as the cost of the innovative biologics are enormously high and even minimal reduction in price will reduce the healthcare spending substantially. All the countries are focusing on reducing the healthcare expenditure and biosimilars compliments to this goal. Biologic products are complex in structure and follow a complex manufacturing process thus, some variation exists between the reference product and its biosimilar. It is very important to assess the variations in biosimilars by comparing with reference product to ensure quality, non-clinical, and clinical properties, which has given rise to the regulatory requirements for biosimilars. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
BIOSIMILARS - Regulatory Framework and Pipeline Analysis Regulatory requirement for approving biosimilars varies across different regulatory bodies. However, all the countries have derived the basic theme from EMA and WHO guidelines for framing their regulatory structure. There is a need to harmonize the nomenclature of biosimilars, extrapolation of indications, and interchangeability of biosimilars with reference products across the regulatory bodies. Biosimilars market is developing and it could be well established with the pipeline that is poised to deliver a wave of biosimilars in the market in the near future ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
BIOSIMILARS - Regulatory Framework and Pipeline Analysis Scope: • Introduction • Market dynamics: Trends, Drivers, and Barriers • WHO guidance for biosimilars • Regulatory overview, biosimilar guidelines, regulatory framework for biosimilars, and market outlook for: Europe, USA, India, South Korea, Japan and China. • Key players • Pipeline Analysis ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
BIOSIMILARS - Regulatory Framework and Pipeline Analysis Reasons to Buy: • Understand the regulatory requirement and regulatory framework that facilitates effective product development strategy as biosimilars industry is currently highly focused, growing, and outpacing the growth rate of small molecule pharmaceutical market • Targeting geographies would be easy by comparing different regulatory frameworks; this would also provide a base for designing a strategy to enter the developed markets. Biosimilars are of interest in developed countries to reduce the healthcare expenditure ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441
BIOSIMILARS - Regulatory Framework and Pipeline Analysis For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441